GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Orient Pharma Co 4166.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

22.55

+2.50%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Orient Pharma Co

Its shares trade on Taipei Exchange under the ticker 4166.TWO. It has been listed since 15 June 2012. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.40bn and net income of TWD 208.4m. At that date it held total assets of TWD 2.94bn and shareholders' equity of TWD 2.56bn.

Orient Pharma Co., Ltd. engages in the research, development, and production of pharmaceutical products. The company is headquartered in Taipei City, Taipei. The company went IPO on 2012-06-15. The firm's main products include hyperlipidemic drugs, diabetes drugs, cardiovascular drugs and drugs for musculoskeletal diseases. The firm is also involved in the original equipment manufacturer (OEM) manufacturing business and clinical trial business. The firm distributes its products in domestic market and to overseas markets, such as the United States, Ireland and mainland China.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
15 Jun 2012
Employees
21

Leadership

Pay as last reported

  • Mr. Jinh-Hong TsaiChairman of the Board, since 2008
  • Chuntong HuangGeneral Manager
  • Mr. Yujian XiaoDeputy General Manager-Global Business Division
  • Ms. Yi-Hsin ChangHead of Finance & Accounting
  • Bihua LinCorporate Governance Officer
  • Mr. Weichao GaoDirector
  • Mr. Kexin HuDirector
  • Mr. Weng-Foung HuangDirector
  • Ms. Yuling LiDirector
  • Mr. Mon Lin TsaiDirector, since 2008
  • Mr. Tai-Ming ChenIndependent Director
  • Mr. K.C. ChouIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Orient Pharma's hyperlipidemic drugs are widely used in Taiwan's domestic market.
  • The company's OEM manufacturing business supports global pharmaceutical clients.
  • Orient Pharma's cardiovascular drugs are distributed in the United States and Ireland.

Weaknesses

  • The company has only 21 employees, limiting operational capacity.
  • Orient Pharma's product range is limited to specific drug categories.
  • The firm's clinical trial business is not well-established in international markets.

Opportunities

  • Expanding into mainland China's growing pharmaceutical market offers significant potential.
  • Increasing demand for diabetes drugs in the United States presents new opportunities.
  • Orient Pharma can leverage its OEM manufacturing to enter new international markets.

Threats

  • Competition from larger pharmaceutical firms in the Health Care sector.
  • Regulatory changes in the United States could affect drug distribution.
  • Economic instability in mainland China may impact market growth.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.